Status In progress
Process STA 2018
ID number 1421

Provisional Schedule

Committee meeting: 2 05 September 2019

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick


Companies sponsors Alimera Sciences (fluocinolone acetonide)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Diabetes UK
  Fight for Sight
Professional groups Royal College of Ophthalmologists
  Royal College of Physicians


Assessment group None
Comparator companies Allergan UK
  Bayer plc
  Novartis Pharmaceuticals
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups National Institute for Health Research


Key events during the development of the guidance:

Date Update
31 July 2019 - 21 August 2019 Appraisal consultation
10 July 2019 Committee meeting: 1
18 March 2019 This appraisal topic will no longer be considered at the committee meeting of 3 April 2019. The appraisal of fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (part review of TA301) [ID1421] committee meeting date will be rescheduled to allow the company (Alimera) additional time to provide new evidence. The new committee meeting date will be communicated, once confirmed.
24 October 2018 Invitation to participate
30 November 2010 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance